Type 2 diabetes is a significant burden on the healthcare system with unique challenges in the value-based payment system. Although there are a variety of antidiabetic medications with clinical benefit, access to newer treatments are often limited …

Adolescent polycystic ovary syndrome (PCOS) is characterized by androgen excess and oligo-amenorrhea, and commonly results from a mismatch between early adipogenesis and later lipogenesis, thus from a mismatch between the capacity and the demand …

Over the past two decades, molecular targeted therapy has revolutionized the landscape of cancer treatment due to lower side effects as well as higher anticancer effects. Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the …

Pioglitazone ameliorates liver dysfunction in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD); however, its efficacy in T2D patients with alcoholic fatty liver disease (AFLD) is unclear. Here, we conducted a …

Elevated serum fibroblast growth factor-23 (FGF23) levels are the earliest findings in chronic kidney disease (CKD) with mineral bone metabolism disorders and its levels contribute to high rates of left ventricular hypertrophy, cardiovascular …

Nephrotic syndrome (NS) affects 1.15–16.9 children per 100,000 and is most commonly primary and idiopathic [ 1 ]. While glucocorticoids (GC) have been the primary treatment for idiopathic NS patients for  > 60 years, there is still no treatment …

Tyrosine kinase inhibitors (TKIs) have improved outcomes of chronic myeloid leukemia (CML). However, 20–30% of patients require second-line TKIs following suboptimal response. The cost and adverse events limit their use in resource-constraint …

In dieser pragmatisch angelegten Studie führte der zusätzliche Einsatz von Sulfonylharnstoffen oder Pioglitazon zu einer Verbesserung der Diabeteseinstellung. Allerdings traten unter Sulfonylharnstoffen bei 508 von 1493 Patienten während der …